Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) announced positive results from its human clinical study HYPER-H21-4, demonstrating significant and sustained blood pressure (BP) reductions in hypertensive patients using its DehydraTECH-CBD formulation. Key findings include an average systolic BP reduction of up to 7.01 mmHg over five weeks, with no serious adverse events reported. The study suggests potential additive BP lowering effects for patients on standard medications. Lexaria plans to advance into a Phase Ib clinical study with the U.S. FDA.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced the appointment of Dr. Catherine Turkel to its board of directors, enhancing its leadership at a pivotal time. Dr. Turkel brings over 20 years of experience in the pharma and biotech sector, notably leading global drug development programs. Her expertise in regulatory strategy and commercial planning, particularly with Allergan's BOTOX program, is expected to advance Lexaria's DehydraTECH technology, which enhances the delivery of active pharmaceutical ingredients. Lexaria is positioned for continued growth following a successful pre-IND meeting with the FDA.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced the granting of its 27th international patent in Mexico under registration #390001. This patent is part of Lexaria's third patent family, covering Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, which has also received recognition in Australia, India, and Japan. The patent allows the use of DehydraTECH-processed non-psychoactive cannabinoids to treat various disorders, including hypertension and neurological diseases. Lexaria continues its regulatory pursuit for DehydraTECH-CBD in pharmaceutical applications.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) recently provided insights on third-party valuation methods for biotech firms. Highlighting the lengthy and costly drug development process, the company noted that its DehydraTECH-CBD program is advancing through FDA's clinical research phase. Valuation metrics show significant potential for drugs in different clinical trial phases, with estimated valuations of $88 million, $248 million, and $1.12 billion at the start of Phase I, II, and III, respectively. Lexaria indicated that pursuing the FDA's 505(b)(2) regulatory pathway could enhance approval prospects.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a new broadcast titled, "The Power of Science to Stop a Killer," focusing on its patented drug-delivery technology, DehydraTECH(TM). This innovation enhances the absorption of active pharmaceutical ingredients (APIs), potentially addressing the global anti-hypertensive market, valued at $24.17 billion in 2020 and projected to reach $27.81 billion by 2025. Hypertension contributes to significant healthcare costs, estimated at $131 billion annually in the U.S., with over 670,000 related deaths in 2020.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces its feature in a NetworkNewsWire editorial, highlighting advancements in hypertension treatment. With nearly 114 million American adults affected by hypertension, the company leverages its patented DehydraTECH(TM) technology to enhance drug delivery, potentially revolutionizing hypertension therapeutics. Lexaria's technology improves bioabsorption of active ingredients, reducing onset time significantly. The firm holds 25 patents and has 50 more pending, promoting its innovative approach in the pharmaceutical landscape.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful completion of dosing in its clinical hypertension study, HYPER-H21-4, involving 64 patients. The study was randomized, double-blind, and placebo-controlled, aimed at assessing the safety and efficacy of DehydraTECH-CBD. Notably, no serious adverse events were reported, marking a significant safety milestone. The findings are anticipated to support an IND application to the FDA for further clinical testing. Secondary outcomes will include various cardiovascular health metrics, brain function, and overall health assessments, with data analyses expected to begin in September.
Lexaria Bioscience Corp. has issued a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals for the European, Australian, and New Zealand markets. The license allows AnodGen to manufacture and distribute cannabinoid active pharmaceutical ingredient powders and mandates royalty payments to Lexaria for all sales. This partnership aims to enhance bioavailability and absorption of cannabinoid products. AnodGen plans to operationalize its facility in Ireland by the end of 2022, aiming for significant growth in the pharmaceutical sector.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has filed a pre-Investigational New Drug (IND) meeting request with the FDA, successfully initiating communication regarding its DehydraTECH-CBD for hypertension treatment. The FDA confirmed receipt and set a target date of July 30, 2022 for follow-up, contingent on meeting specific conditions. This meeting aims to clarify Lexaria's IND-enabling development program ahead of a full IND application expected later in 2022 or early 2023. The hypertension market, valued at $28 billion, presents significant potential for Lexaria's innovative drug delivery technology.
Lexaria Bioscience Corp. (LEXXW, LEXX) has entered into a significant licensing agreement with Premier Wellness Science Co., Ltd. to utilize its DehydraTECH technology in the Japanese non-pharmaceutical market. Premier will make minimum payments of US$4,527,500 over five years to retain exclusivity, along with receiving royalty revenue from product sales. This partnership aims to address the booming Japanese CBD market, projected to exceed US$35 billion annually. Premier's parent company reported US$187 million in revenue for the first three quarters of 2021, signaling robust market potential.